http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105283457-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2014-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105283457-B |
| titleOfInvention | 4- amino -6- phenyl -5,6- glyoxalidine as beta-secretase (BACE) inhibitor simultaneously [1,5-A] pyrazines derivatives |
| abstract | The present invention relates to novel 5 as beta-secretase inhibitors, 6 glyoxalidine simultaneously [1,5 a] pyrazine radical derivative, beta-secretase is also referred to as the sites β amyloid protein lyases, BACE, especially BACE1 and/or BACE2 (wherein BACE1 is also referred to as Asp2 or film aspartic protease 2, and BACE2 is also referred to as Asp1, film aspartic protease 1 or DRAP).The invention further relates to the pharmaceutical compositions for including such compound, it is related to preparing such compound and the method for composition, and it is related to such compound and composition is used to prevent and treat the purposes for the obstacle for being directed to beta-secretase, these obstacles are such as Alzheimer disease (AD), mild cognitive impairment, aging, it is dull-witted, dementia with Lewy body, Down syndrome, with the relevant dementia of apoplexy, with the relevant dementia of Parkinson's disease, alzheimer dementia, with the relevant dementia of amyloid beta, age-related macular degeneration, diabetes B and other dysbolisms. |
| priorityDate | 2013-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 280.